Skip to main

Media Library

Access a wide range of videos, podcasts, and webinars, with exclusive content just for ASGCT members.

Dive deeper into the full collection of content waiting for you below.

Explore Our Latest Podcast Releases

The Issue | ASGCT Podcast Network
PODCAST: The Issue | November 10, 2026

Beyond the Liver: Dr. Anastasia Khvorova on the Future of Extrahepatic siRNA Delivery

1 hr, 4 mins

PODCAST: The Molecular Therapy Podcast | November 5, 2026

The Future of Molecular Therapy Nucleic Acids

40 mins

PODCAST: Scientists, Unedited | November 3, 2026

The Long Road from Bench to Clinic: A Conversation with Dr. Luigi Naldini on Science, Family, and the Courage to Build Something New

50 mins

Search + Filter the Entire Library

1-10 of 725 media results


Beyond the Liver: Dr. Anastasia Khvorova on the Future of Extrahepatic siRNA Delivery

Dr. Anastasia Khvorova of UMass Chan Medical School joins The Issue Podcast to discuss the next frontier of siRNA therapeutics and delivery beyond the liver. She covers the kidney clearance barrier, local versus systemic delivery, how RNAi and gene editing complement each other, and where she expects the field to go over the next several years.

The Issue

The Future of Molecular Therapy Nucleic Acids

We are excited to announce that Dr. Paloma Giangrande has committed to a second term as Editor-in-Chief of Molecular Therapy Nucleic Acids (MTNA). In this episode, Dr. Marcin Kortylewski, the Oligonucleotides: Therapies and Applications section editor of MTNA, interviews Paloma about her journey into science and RNA biology, her perspectives on therapeutic development, her initiatives during her first term as Editor-in-Chief, and her vision for MTNA in the next five years. 

Molecular Therapy

The Long Road from Bench to Clinic: A Conversation with Dr. Luigi Naldini on Science, Family, and the Courage to Build Something New

In this episode of Scientists, Unedited, Luigi Naldini, PhD, Professor of Cell and Tissue Biology and of Gene and Cell Therapy at the San Raffaele University School of Medicine and Scientific Director of the San Raffaele Telethon Institute for Gene Therapy, joins host Eirini Vamva, PhD, for a discussion on his story. Dr. Naldini, a pioneer of lentiviral vectors, reflects on the unexpected path that led him to gene therapy and helped turn a bold scientific idea into a clinical reality. He discusses the risks, setbacks, collaborations, and family support that shaped his career, as well as the future of gene therapy and why meaningful scientific progress requires persistence, teamwork, and time.

podcast

2025 Advancing Cell & Gene Therapies for Cancer: Oncolytic Viruses - New Paradigms

Chair: Chair: Paola Grandi, PhD, Adze Biotechnology Richard Vile, PhD, Mayo Clinic: Oncolytic Viruses as Lymphoeditors in Cancer Immunotherapy Eva Galanis, MD, Mayo: First in human testing of engineered oncolytic measles virus strains for glioma immunovirotherapy


2025 Advancing Cell & Gene Therapies for Cancer: Cell Therapies - New Paradigms

Chairs: Sarwish Rafiq, PhD, Emory University and Michael Milone, MD, PhD, University of Pennsylvania Renier Brentjens, MD, PhD, Roswell Park Comprehensive Cancer Center: Armored CAR T-cells for the treatment of solid tumors Todd Fehniger, MD, PhD, Washington University Medicine: Molecular programming and engineering NK cells for enhanced immunotherapy Leyuan Ma, PhD, Children’s Hospital of Philadelphia: CAR T boosting vaccine and its unexpected bystander effects on solid tumor control


2025 Advancing Cell & Gene Therapies for Cancer: Oral Abstracts

Synthetic reprogramming of γδ CAR t cells with the ltbr gene for the generation of long lived, highly potent and immunosuppression-resistant allogeneic therapy of solid tumors Theodoros Giavridis, Ph.D., OverT Bio Selection gene drive therapy proactively combats drug resistance to targeted therapy in mice Scott M Leighow, Ph.D., Red Ace Bio Restoration of RB tumor suppressor function in retinoblastoma via GPC2-targeted RB1 mRNA lipid nanoparticles Grant P Grothusen, Ph.D., Children's Hospital of Philadelphia Identification of host factors and mechanism-based therapeutic combinations to enhance the antitumor potential of oncolytic viruses in pancreatic cancer Pierre Cordelier, Ph.D.-HDR, Inserm


2025 Advancing Cell & Gene Therapies for Cancer: Barriers and Opportunities/Mechanisms of Resistance (1)

Chairs: Balveen Kaur, PhD, Augusta University and Maria Castro, PhD, University of Michigan Medical School Balveen Kaur, PhD, Augusta University: Barriers and Opportunities for Oncolytic viral therapy Maria Castro, PhD, University of Michigan Medical School: Epigenetic reprogramming of the tumor immune microenvironment impacts the efficacy of immune mediated gene therapies


2025 Advancing Cell & Gene Therapies for Cancer: Cell and Viral Therapy Combinatorial Approaches

Chair: Saad Kenderian, PhD, Mayo Clinic Masataka Suzuki, PhD, Baylor: Combination treatment with Oncolytic Virus and CAR-T cell Sidi Chen, PhD, Yale: Gene editing for cell and gene therapy in oncology


2025 Advancing Cell & Gene Therapies for Cancer: The Synergy Era: Viruses, Cells, and Genes Converging for a Cure

Evanthia Galanis, MD Maria Castro, PhD Todd Fehniger, MD, PhD Paola Grandi, PhD


2025 Advancing Cell & Gene Therapies for Cancer: Barriers and Opportunities/Mechanisms of Resistance (2)

Chair: Maria Castro, PhD, University of Michigan Medical School Benjamin Deverman, PhD, Broad Institute: Efficient BBB crossing with human transferrin receptor-binding AAV capsids David Liu, PhD, Harvard: Predicting resistant patients and therapeutic targets in immune checkpoint treated metastatic melanoma